ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of “Moderate Buy” from Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $18.6667.

Several analysts have weighed in on the company. Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, Raymond James Financial started coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective on the stock.

ADMA Biologics Price Performance

ADMA stock opened at $8.90 on Thursday. The firm has a 50 day moving average of $9.21 and a 200-day moving average of $9.89. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 12.71 and a beta of 0.78. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.14 EPS. As a group, equities analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sequoia Financial Advisors LLC purchased a new stake in ADMA Biologics in the 2nd quarter valued at approximately $89,000. Tidal Investments LLC purchased a new position in ADMA Biologics during the second quarter worth $148,000. Integrated Wealth Concepts LLC purchased a new position in ADMA Biologics during the second quarter worth $42,000. NewEdge Advisors LLC raised its holdings in shares of ADMA Biologics by 9,423.3% in the second quarter. NewEdge Advisors LLC now owns 23,332 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 23,087 shares during the last quarter. Finally, Mraz Amerine & Associates Inc. acquired a new position in shares of ADMA Biologics in the second quarter worth $148,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.